PILA PHARMA AB acquired TRPV1 antagonists from Ario Pharma Limited on March 30, 2016. Under the terms of the agreement, the acquired assets include a series of small molecule TRPV1 antagonists including the clinical ready and safe development candidate XEN-D0501, patents, know-how and data.

PILA PHARMA AB completed the acquisition of TRPV1 antagonists from Ario Pharma Limited on March 30, 2016.